Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trial. [electronic resource]
Producer: 20051020Description: 1506-12 p. digitalISSN:- 0195-668X
- Abciximab
- Adult
- Aged
- Angina Pectoris -- drug therapy
- Antibodies, Monoclonal -- administration & dosage
- Anticoagulants -- administration & dosage
- Bundle-Branch Block -- drug therapy
- Coronary Restenosis -- etiology
- Coronary Stenosis -- drug therapy
- Drug Therapy, Combination
- Female
- Fibrinolytic Agents -- administration & dosage
- Hemorrhage -- chemically induced
- Humans
- Immunoglobulin Fab Fragments -- administration & dosage
- Injections, Intravenous
- Male
- Middle Aged
- Myocardial Infarction -- etiology
- Partial Thromboplastin Time -- mortality
- Recombinant Proteins -- administration & dosage
- Recurrence
- Regression Analysis
- Survival Analysis
- Tissue Plasminogen Activator -- administration & dosage
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.